Company: NCEL
Filing Date: 2025-09-03
Form Type: F-4/A
Source: 0001213900-25-084157
Chunk: 288

Company: NewcelX Ltd.
Filing Date: 2025-09-03
Form: F-4/A
Chunk 288
---
2,206,000 (cash compensation including all applicable social security contributions) for the variable compensation of the Company’s executive officers, (iii) to approve the grant of equity or equity linked instruments with maximum aggregate amount of CHF 991,000 (equity or equity linked instruments including all applicable social security contributions) for the Company’s executive officers, and (iv) to approve the participation in the purchase of a run -offinsurance policy for the Company’s executive officers, to be effective at the time of the Merger’s completion, with coverage amounts and terms to be approved by the Board of Directors, in each case for each of, the financial year 2025 and the financial year 2026. To approve each of Proposals 12.1 and 12.2, a resolution passed by a Simple Majority Vote is required. You may vote “FOR,” “AGAINST” or “ABSTAIN” on each of Proposals 12.1 through 12.2. A failure to vote, an abstention or a broker non -vote, if any, will have the same effect as a vote “AGAINST” each of Proposals 12.1 through 12.2. THE NLS BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE
“FOR” EACH OF PROPOSALS 12.1 THROUGH 12.2. 123 ADVISORY VOTE: APPROVAL OF CONTINGENT VALUE RIGHTS (CVR) AGREEMENT
(PROPOSAL 13) The Company intends to work towards selling its existing R&D assets under development, excluding the DOXA asset, as part of the CVR Agreement. The combined company intends to develop the DOXA R&D asset, which will remain with the combined company (both independently and in combination with the company’s diabetes product). The remaining assets of the Company are intended to be reorganized under the CVR Agreement for the purpose of being sold by a committee to be established specifically for this purpose and responsible for executing the sale. The CVR Recipients are expected to be entitled to receive the net proceeds from the sale of the divested business, if and when it is sold, through mechanisms including Contingent Value Rights. It should be noted that if the divested business generates negative cash flow and/or profitability at the end of any fiscal quarter (except for intellectual property maintenance costs of up to $100,000 per calendar year), the combined company will have the right to cease the sale process of the divested business